3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma
2
Leukemia
2
Recurrence
1
Burkitt Lymphoma
1
Interventions
Temozolomide
3
Gemcitabine
3
Etoposide
3
pembrolizumab
2
Rituximab
2
Lomustine
2
Haloperidol
2
Dexamethasone
2
Cyclosporine
2
vocimagene amiretrorepvec
1
trofosfamide
1
tinostamustine
1
selinexor
1
ruxolitinib
1
regorafenib
1
peginterferon alfa-2b
1
osimertinib
1
menatetrenone
1
interferon gamma-1b
1
interferon gamma, Cys(-3), Tyr(-2), Cys(-1)-
1
imetelstat
1
glumetinib
1
fludarabine
1
etoposide phosphate
1
eculizumab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carbon-11 acetate
1
blinatumomab
1
auricularum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recurrence
×
Asparaginase
×
Clear all
NCT01518517
2022-02-02
GRASPIVOTALL
ERYtech Pharma
Phase 2/3
Completed
85 enrolled
13 charts